Ashwin Basavaraj1, Radmila Choate2, Doreen Addrizzo-Harris3, Timothy R Aksamit4, Alan Barker5, Charles L Daley6, M Leigh Anne Daniels7, Edward Eden8, Angela DiMango9, Kevin Fennelly10, David E Griffith11, Margaret M Johnson12, Michael R Knowles7, Mark L Metersky13, Peadar G Noone7, Anne E O'Donnell14, Kenneth N Olivier10, Matthias A Salathe15, Andreas Schmid15, Byron Thomashow9, Gregory Tino16, Kevin L Winthrop17. 1. New York University School of Medicine, New York, NY. Electronic address: Ashwin.basavaraj@nyulangone.org. 2. Research, the COPD Foundation, Miami, FL; College of Public Health, University of Kentucky, Lexington, KY. 3. New York University School of Medicine, New York, NY. 4. Pulmonary Disease and Critical Care Medicine, Mayo Clinic, Rochester, MN. 5. Department of Pulmonology, OHSU School of Medicine, Portland, OR. 6. Division of Mycobacterial and Respiratory Infections, National Jewish Health, Denver, CO. 7. University of North Carolina at Chapel Hill, Chapel Hill, NC. 8. Icahn School of Medicine, Mt Sinai West and Mt Sinai St Luke's Hospitals, Mt Sinai, NY. 9. Center for Chest Disease, Columbia College of Physicians and Surgeons, New York, NY. 10. National Heart Lung and Blood Institute, NIH, Bethesda, MD. 11. University of Texas at Tyler, Tyler, TX. 12. Pulmonary and Critical Care, Mayo Clinic Florida, Jacksonville, FL. 13. Division of Pulmonary and Critical Care Medicine, University of Connecticut School of Medicine, Farmington, CT. 14. Georgetown University Medical Center, Washington, DC. 15. University of Miami Miller School of Medicine, Miami, FL. 16. University of Pennsylvania Perelman School of Medicine, Philadelphia, PA. 17. Department of Pulmonology, OHSU School of Medicine, Portland, OR; Department of Infectious Disease, OHSU School of Medicine, Portland, OR.
Abstract
BACKGROUND: In patients with bronchiectasis, airway clearance techniques (ACTs) are important management strategies. RESEARCH QUESTION: What are the differences in patients with bronchiectasis and a productive cough who used ACTs and those who did not? What was the assessment of bronchiectasis exacerbation frequency and change in pulmonary function at 1-year follow up? STUDY DESIGN AND METHODS: Adult patients with bronchiectasis and a productive cough in the United States Bronchiectasis and NTM Research Registry were included in the analyses. ACTs included the use of instrumental devices and manual techniques. Stratified analyses of demographic and clinical characteristics were performed by use of ACTs at baseline and follow up. The association between ACT use and clinical outcomes was assessed with the use of unadjusted and adjusted multinomial logistic regression models. RESULTS: Of the overall study population (n = 905), 59% used ACTs at baseline. A greater proportion of patients who used ACTs at baseline and follow up continuously had Pseudomonas aeruginosa (47% vs 36%; P = .021) and experienced an exacerbation (81% vs 59%; P < .0001) or hospitalization for pulmonary illness (32% vs 22%; P = .001) in the prior two years, compared with those patients who did not use ACTs. Fifty-eight percent of patients who used ACTs at baseline did not use ACTs at 1-year follow up. There was no significant change in pulmonary function for those who used ACTs at follow up, compared with baseline. Patients who used ACTs at baseline and follow up had greater odds for experiencing exacerbations at follow up compared with those patients who did not use ACTs. INTERPRETATION: In patients with bronchiectasis and a productive cough, ACTs are used more often if the patients have experienced a prior exacerbation, hospitalization for pulmonary illness, or had P aeruginosa. There is a significant reduction in the use of ACTs at 1-year follow up. The odds of the development of a bronchiectasis exacerbation are higher in those patients who use ACTs continuously, which suggests more frequent use in an ill bronchiectasis population.
BACKGROUND: In patients with bronchiectasis, airway clearance techniques (ACTs) are important management strategies. RESEARCH QUESTION: What are the differences in patients with bronchiectasis and a productive cough who used ACTs and those who did not? What was the assessment of bronchiectasis exacerbation frequency and change in pulmonary function at 1-year follow up? STUDY DESIGN AND METHODS: Adult patients with bronchiectasis and a productive cough in the United States Bronchiectasis and NTM Research Registry were included in the analyses. ACTs included the use of instrumental devices and manual techniques. Stratified analyses of demographic and clinical characteristics were performed by use of ACTs at baseline and follow up. The association between ACT use and clinical outcomes was assessed with the use of unadjusted and adjusted multinomial logistic regression models. RESULTS: Of the overall study population (n = 905), 59% used ACTs at baseline. A greater proportion of patients who used ACTs at baseline and follow up continuously had Pseudomonas aeruginosa (47% vs 36%; P = .021) and experienced an exacerbation (81% vs 59%; P < .0001) or hospitalization for pulmonary illness (32% vs 22%; P = .001) in the prior two years, compared with those patients who did not use ACTs. Fifty-eight percent of patients who used ACTs at baseline did not use ACTs at 1-year follow up. There was no significant change in pulmonary function for those who used ACTs at follow up, compared with baseline. Patients who used ACTs at baseline and follow up had greater odds for experiencing exacerbations at follow up compared with those patients who did not use ACTs. INTERPRETATION: In patients with bronchiectasis and a productive cough, ACTs are used more often if the patients have experienced a prior exacerbation, hospitalization for pulmonary illness, or had P aeruginosa. There is a significant reduction in the use of ACTs at 1-year follow up. The odds of the development of a bronchiectasis exacerbation are higher in those patients who use ACTs continuously, which suggests more frequent use in an ill bronchiectasis population.
Authors: David E Griffith; Timothy Aksamit; Barbara A Brown-Elliott; Antonino Catanzaro; Charles Daley; Fred Gordin; Steven M Holland; Robert Horsburgh; Gwen Huitt; Michael F Iademarco; Michael Iseman; Kenneth Olivier; Stephen Ruoss; C Fordham von Reyn; Richard J Wallace; Kevin Winthrop Journal: Am J Respir Crit Care Med Date: 2007-02-15 Impact factor: 21.405
Authors: Stefano Aliberti; Sarah Masefield; Eva Polverino; Anthony De Soyza; Michael R Loebinger; Rosario Menendez; Felix C Ringshausen; Montserrat Vendrell; Pippa Powell; James D Chalmers Journal: Eur Respir J Date: 2016-06-10 Impact factor: 16.671
Authors: Timothy R Aksamit; Anne E O'Donnell; Alan Barker; Kenneth N Olivier; Kevin L Winthrop; M Leigh Anne Daniels; Margaret Johnson; Edward Eden; David Griffith; Michael Knowles; Mark Metersky; Matthias Salathe; Byron Thomashow; Gregory Tino; Gerard Turino; Betsy Carretta; Charles L Daley Journal: Chest Date: 2016-11-23 Impact factor: 9.410
Authors: Edward Eden; Radmila Choate; Alan Barker; Doreen Addrizzo-Harris; Timothy R Aksamit; Charles L Daley; M Leigh Anne Daniels; Angela DiMango; Kevin Fennelly; David E Griffith; Margaret M Johnson; Michael R Knowles; Mark L Metersky; Peadar G Noone; Anne E O'Donnell; Kenneth N Olivier; Matthias A Salathe; Andreas Schmid; Byron Thomashow; Gregory Tino; Gerard M Turino; Kevin L Winthrop Journal: Chronic Obstr Pulm Dis Date: 2019-04-09
Authors: Amanda R McCullough; Michael M Tunney; Alexandra L Quittner; J Stuart Elborn; Judy M Bradley; Carmel M Hughes Journal: BMC Pulm Med Date: 2014-07-01 Impact factor: 3.317
Authors: Eva Polverino; Pieter C Goeminne; Melissa J McDonnell; Stefano Aliberti; Sara E Marshall; Michael R Loebinger; Marlene Murris; Rafael Cantón; Antoni Torres; Katerina Dimakou; Anthony De Soyza; Adam T Hill; Charles S Haworth; Montserrat Vendrell; Felix C Ringshausen; Dragan Subotic; Robert Wilson; Jordi Vilaró; Bjorn Stallberg; Tobias Welte; Gernot Rohde; Francesco Blasi; Stuart Elborn; Marta Almagro; Alan Timothy; Thomas Ruddy; Thomy Tonia; David Rigau; James D Chalmers Journal: Eur Respir J Date: 2017-09-09 Impact factor: 16.671
Authors: Elizabeth Smith; Max Thomas; Ebru Calik-Kutukcu; Irene Torres-Sánchez; Maria Granados-Santiago; Juan Carlos Quijano-Campos; Karl Sylvester; Chris Burtin; Andreja Sajnic; Jana De Brandt; Joana Cruz Journal: ERJ Open Res Date: 2021-02-08
Authors: Artmis Youssefnia; Alicia Pierre; Jeffrey M Hoder; Michelle MacDonald; Monica J B Shaffer; Jessica Friedman; Philip S Mehler; Amanda Bontempo; Francisco C N da Silva; Edward D Chan Journal: J Thorac Dis Date: 2022-09 Impact factor: 3.005